Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy

Bhave, P; Hong, A; Lo, SN; Johnson, R; Mangana, J; Johnson, DB; Dulgar, O; Eroglu, Z; Yeoh, HL; Haydon, A; Lodde, GC; Livingstone, E; Khattak, A; Kahler, K; Hausschild, A; McArthur, GA; Menzies, AM; Long, G; Wang, W; Carlino, MS

Author(s): Bhave, P; Hong, A; Lo, SN; Johnson, R; Mangana, J; Johnson, DB; Dulgar, O; Eroglu, Z; Yeoh, HL; Haydon, A; Lodde, GC; Livingstone, E; Khattak, A; Kahler, K; Hausschild, A; McArthur, GA; Menzies, AM; Long, G; Wang, W; Carlino, MS;
Details: Publication Year 2023-03,Volume 11,Issue #3,Page e006629
Journal Title: Journal for ImmunoTherapy of Cancer
Publication Type: Research article
Abstract: BACKGROUND: In patients with stage III melanoma, despite surgical resection and adjuvant systemic therapy, locoregional recurrences still occur. The randomized, phase III Trans-Tasman Radiation Oncology Group (TROG) 02.01 trial demonstrated that adjuvant radiotherapy (RT) after complete lymphadenectomy (CLND) halves the incidence of melanoma recurrence within local nodal basins without improving overall survival or quality of life. However, the study was conducted prior to the current era of adjuvant systemic therapies and when CLND was the standard approach for microscopic nodal disease. As such, there is currently no data on the role of adjuvant RT in patients with melanoma who recur during or after adjuvant immunotherapy, including those that may or may not have undergone prior CLND. In this study, we aimed to answer this question. METHODS: Patients with resected stage III melanoma who received adjuvant anti-programmed cell death protein-1 (PD-1) (+/-ipilimumab) immunotherapy with a subsequent locoregional (lymph node and/or in-transit metastases) recurrence were retrospectively identified. Multivariable logistic and Cox regression analyses were conducted. Primary outcome was rate of subsequent locoregional recurrence; secondary outcomes were locoregional recurrence-free survival (lr-RFS2) and overall RFS (RFS2) to second recurrence. RESULTS: In total, 71 patients were identified: 42 (59%) men, 30 (42%) BRAF V600E mutant, 43 (61%) stage IIIC at diagnosis. Median time to first recurrence was 7 months (1-44), 24 (34%) received adjuvant RT and 47 (66%) did not. Thirty-three patients (46%) developed a second recurrence at a median of 5 months (1-22). The rate of locoregional relapse at second recurrence was lower in those who received adjuvant RT (8%, 2/24) compared with those who did not (36%, 17/47, p=0.01). Adjuvant RT at first recurrence was associated with an improved lr-RFS2 (HR 0.16, p=0.015), with a trend towards an improved RFS2 (HR 0.54, p=0.072) and no effect on risk of distant recurrence or overall survival. CONCLUSION: This is the first study to investigate the role of adjuvant RT in patients with melanoma with locoregional disease recurrence during or after adjuvant anti-PD-1-based immunotherapy. Adjuvant RT was associated with improved lr-RFS2, but not risk of distant recurrence, demonstrating a likely benefit in locoregional disease control in the modern era. Further prospective studies are required to validate these results.
Publisher: BMJ
Keywords: Male; Humans; Female; Radiotherapy, Adjuvant; *Quality of Life; Retrospective Studies; Neoplasm Recurrence, Local/pathology; *Melanoma/drug therapy/pathology; Adjuvants, Immunologic; Immunotherapy/methods; immune checkpoint inhibitors; immunotherapy; melanoma; radiotherapy
Department(s): Medical Oncology
PubMed ID: 36889810
Publisher's Version: https://doi.org/10.1136/jitc-2022-006629
Open Access at Publisher's Site: https://doi.org/10.1136/jitc-2022-006629
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-06-22 07:56:50

Last Modified: 2024-10-24 03:38:51